JNJNYSESEC EDGAREDGAR

JOHNSON & JOHNSON

Pharmaceutical Preparations·NEW BRUNSWICK, NJ·FY end 01/03·CIK 200406

Board of Directors

12 members · 11 independent · FY 2025
DirectorRoleTenureAgeCommitteesIndep.Annual fees
Mary C. Beckerle, Ph.D.Director10y71TechRegulatory Compliance & Sustainability
Jennifer A. Doudna, Ph.D.Director7y62NCGTech
Joaquin DuatoCEO and Director3y63Finance
Marillyn A. HewsonLead Independent Director6y72NCGCompFinance$413,000
Paula A. Johnson, M.D.Director2y66NCGTech
Hubert JolyDirector6y66AuditNCG$367,548
Mark B. McClellan, M.D., Ph.D.Director12y62Regulatory Compliance & SustainabilityTech
John G. MorikisDirector1y62AuditComp
Daniel E. PintoDirector1y63AuditComp
Mark A. WeinbergerDirector6y64Regulatory Compliance & SustainabilityAudit$355,000
Nadja Y. West, M.D.Director5y64Regulatory Compliance & SustainabilityTech
Eugene A. WoodsDirector2y61CompRegulatory Compliance & Sustainability$347,158

Risk-factor diff

FY 2025 10-K vs. FY 2024
+16 new8 removed

Net-new paragraphs in the most recent 10-K's Item 1A. Companies rarely add risk language without a real reason — additions here are often a leading signal of management concerns.

NEW · FY 2025

The Company’s manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company’s subsidiaries operate 63 manufacturing facilities as well as sourcing from thousands of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-s…

NEW · FY 2025

The threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.

NEW · FY 2025

The Company is subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may have a material adverse affect on the Company’s financial condition and business operations.

NEW · FY 2025

Product concerns, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, field actions, such as product recalls, governmental investigations, regulatory action on the part of the U.S. FDA (or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company’s products. Product recalls have in the past, and could in…

NEW · FY 2025

Changes in tax laws or regulations in the U.S. and around the world, including global minimum taxes could negatively impact the Company’s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of the Company’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded in the Company’s Consolidated Statement of Earnings. The Company closely monitors these proposa…

+ 11 more new paragraphs not shown

Policies & disclosures

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.